Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$562.59 USD

562.59
1,383,958

-8.42 (-1.47%)

Updated Nov 30, 2021 04:00 PM ET

After-Market: $562.08 -0.51 (-0.09%) 5:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (180 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

Style Box ETF report for IWP

Cooper Companies' (COO) Buyout to Boost Women's Healthcare

Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.

Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?

Style Box ETF report for VOT

Earnings Estimates Rising for DexCom (DXCM): Will It Gain?

DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Company News for Nov 1, 2021

Companies In The News Are: DXCM, RSG, ABBV, CVX.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

DexCom (DXCM) delivered earnings and revenue surprises of 43.55% and 6.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?

Style Box ETF report for VO

Is a Surprise Coming for DexCom (DXCM) This Earnings Season?

DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil

The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

Nalak Das headshot

5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week

Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.

Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?

Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

DexCom (DXCM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study

Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.

Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y

Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.

The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands

The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands

Mark Vickery headshot

Top Analyst Reports for Edwards Lifesciences, DexCom & Twitter

Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences Corporation (EW), DexCom, Inc. (DXCM), and Twitter, Inc. (TWTR).

Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues

Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.

Catalent (CTLT) Expands Presence in Japan Via New Facility

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.